Literature DB >> 25772757

Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.

Eiji Kunii1, Tetsuya Oguri, Daishi Kasai, Hiroaki Ozasa, Takehiro Uemura, Osamu Takakuwa, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Akio Niimi.   

Abstract

PURPOSE: The purposes of this study were to determine whether organic cation transporters (OCTs) can mediate platinum uptake, and whether OCT down-regulation confers resistance against cisplatin (CDDP) in cancer cells.
METHODS: Two lung cancer cell lines, PC-6 and PC-14, and their CDDP-resistant derivatives, PC-6/CDDP and PC-14/CDDP, were analyzed. OCT expression levels were assayed using quantitative RT-PCR and Western blotting. Additionally, the effect of OCT6 overexpression, induced by transfection of the OCT6 gene SLC22A16 using a forced expression vector, on cellular sensitivity to CDDP and on intracellular platinum accumulation was measured using PC-14/CDDP cells.
RESULTS: Both gene and protein expression of OCT6 were decreased in both CDDP-resistant cell lines compared with their expression in their respective parental cells. Intracellular accumulation of platinum was decreased in PC-14/CDDP cells compared with the parental cells after CDDP treatment. Furthermore, OCT6 overexpression induced by transfection of the OCT6 gene (SLC22A16) forced expression vector-sensitized PC-14/CDDP cells to CDDP and oxaliplatin (L-OHP) concomitant with increased intracellular concentration of platinum.
CONCLUSION: OCT6 is a mediator of platinum uptake in cancer cells, and down-regulation of OCT6 is possibly one of the mechanisms of resistance against cisplatin in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772757     DOI: 10.1007/s00280-015-2723-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.

Authors:  Einav Ratzon; Yousef Najajreh; Rami Salem; Hazem Khamaisie; Martin Ruthardt; Jamal Mahajna
Journal:  BMC Cancer       Date:  2016-02-23       Impact factor: 4.430

2.  Organic cation transporter 6 directly confers resistance to anticancer platinum drugs.

Authors:  Tetsuya Oguri; Eiji Kunii; Satoshi Fukuda; Kazuki Sone; Takehiro Uemura; Osamu Takakuwa; Yoshihiro Kanemitsu; Hirotsugu Ohkubo; Masaya Takemura; Ken Maeno; Yutaka Ito; Akio Niimi
Journal:  Biomed Rep       Date:  2016-10-04

Review 3.  Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.

Authors:  Mohammad Aslam Khan; Kunwar Somesh Vikramdeo; Sarabjeet Kour Sudan; Seema Singh; Annelise Wilhite; Santanu Dasgupta; Rodney Paul Rocconi; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2021-08-18       Impact factor: 15.707

4.  Bacterial over-expression of functionally active human CT2 (SLC22A16) carnitine transporter.

Authors:  Michele Galluccio; Tiziano Mazza; Mariafrancesca Scalise; Maria Chiara Sarubbi; Cesare Indiveri
Journal:  Mol Biol Rep       Date:  2022-05-24       Impact factor: 2.742

Review 5.  Role of SLC transporters in toxicity induced by anticancer drugs.

Authors:  Kevin M Huang; Muhammad Erfan Uddin; Duncan DiGiacomo; Maryam B Lustberg; Shuiying Hu; Alex Sparreboom
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-26       Impact factor: 4.481

6.  Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer.

Authors:  Khine Myint; Riya Biswas; Yan Li; Nancy Jong; Stephen Jamieson; Johnson Liu; Catherine Han; Christopher Squire; Fabrice Merien; Jun Lu; Takeo Nakanishi; Ikumi Tamai; Mark McKeage
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

Review 7.  The Relationship Between Actin Cytoskeleton and Membrane Transporters in Cisplatin Resistance of Cancer Cells.

Authors:  Takahiro Shimizu; Takuto Fujii; Hideki Sakai
Journal:  Front Cell Dev Biol       Date:  2020-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.